title: Study of prolonged administration of lanthanum carbonate in dialysis patients.
abstract: Data of 36 months were accumulated regarding the effects of lanthanum carbonate (LA) on serum phosphate concentrations in dialysis patients. Fifty-three patients (average age and dialysis history 58.4 years and 9.1 years) were included in this study who have been receiving outpatient treatment since March 2009, and who have been unable to maintain serum phosphate concentrations of ≤6.0 mg/dL via traditional therapeutic agents used for hyperphosphatemia. Patients were given dosage of LA in addition to, or instead of, co-hyperphosphatemia treatments already being received. Mean dosages of calcium carbonate (CC) and sevelamer hydrochloride (SH) before starting LA administration were 1301.9 mg and 2462.3 mg, respectively. Dosage of LA for all cases was 750 mg at initial dose; 1528.3 mg at 5 months; and 1416.7 mg at 30 months. Dosage of other phosphate binders were 905.7 mg of CC and 820.8 mg of SH at 5 months; and 687.5 mg of CC and 1031.3 mg of SH at 30 months. Serum phosphorus levels (P levels) were significantly decreased at 1 month of LA administration, and continued until 30 months of La treatment. These results suggest that LA successfully controlled serum P and Ca concentrations simultaneously within target ranges without affecting serum intact parathyroid hormone concentration, although further long-term prospective cohort study on LA would be required.
authors.affiliation: Sapporo Hokuyu Hospital, Sapporo, Japan. gotogoto@hokuyu-aoth.org
authors.forename: Junichi
authors.initials: J
authors.lastname: Gotoh
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Kukita
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Tsuchihashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hattori
authors.forename: Junichi
authors.initials: J
authors.lastname: Iida
authors.forename: Takashi
authors.initials: T
authors.lastname: Horie
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Onodera
authors.forename: Hidenori
authors.initials: H
authors.lastname: Furui
authors.forename: Toru
authors.initials: T
authors.lastname: Tamaki
authors.forename: Junichi
authors.initials: J
authors.lastname: Meguro
authors.forename: Motoki
authors.initials: M
authors.lastname: Yonekawa
authors.forename: Akio
authors.initials: A
authors.lastname: Kawamura
mesh_terms: D000368:Aged; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000627:therapeutic use; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D007811:Lanthanum / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D011073:Polyamines / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D006435:Renal Dialysis / Q000379:methods*; D000069603:Sevelamer; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010710:Phosphates; D011073:Polyamines; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer; D002119:Calcium Carbonate; D002118:Calcium